Phase 3 biotech developing an oncolytic immunotherapy for bladder cancer.
Industry: Health Care
Latest Trade: $38.61 +1.05 (+2.8%)
First Day Return: +95.6%
Return from IPO: +97.7%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 01/02/2024 |
Offer Price | $19.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 20.0 |
Deal Size ($mm) | $380 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 01/24/2024 |
Offer Price | $19.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 20.0 |
Deal Size ($mm) | $380 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Morgan Stanley |
Goldman Sachs |
more |
Company Data | |
---|---|
Headquarters | Irvine, CA, United States |
Founded | 2010 |
Employees at IPO | 61 |
Website cgoncology.com |